Literature DB >> 12955648

Infections due to Haemophilus influenzae serotype E: microbiological, clinical, and epidemiological features.

José Campos1, Federico Román, María Pérez-Vázquez, Jesús Oteo, Belén Aracil, Emilia Cercenado.   

Abstract

Surveillance after introduction of Haemophilus influenzae serotype b vaccination in Spain identified 26 H. influenzae serotype e (HiE) isolates. Of these, 16 (61.5%) were recovered from patients aged >16 years and 10 (38.5%) from children <16 years of age. HiE caused respiratory infections in 14 patients (9 with pneumonia), conjunctivitis in 4, vaginitis in 2, abscess in 2, and cellulitis, peritoneal infection, sepsis and meningitis in 1 patient each. HiE was strongly clonal and highly resistant to ampicillin and cotrimoxazole, and the incidence of HiE infection did not increase over time.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955648     DOI: 10.1086/377232

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  Characteristics of Haemophilus influenzae type b responsible for meningitis in Poland from 1997 to 2004.

Authors:  Anna Skoczyńska; Marcin Kadłubowski; Joanna Empel; Waleria Hryniewicz
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

2.  Haemophilus influenzae infection of a prosthetic knee joint in a patient with CLL: a vaccine preventable disease.

Authors:  Sheema Khan; Srinivasulu Reddy
Journal:  BMJ Case Rep       Date:  2013-11-19

3.  Prevalence and serotype distribution of encapsulated Haemophilus influenzae isolates from patients with lower respiratory tract infections in Poland.

Authors:  Anna Skoczynska; Magdalena Lewandowska; Anna Klarowicz; Waleria Hryniewicz
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

4.  Analysis of invasive Haemophilus influenzae infections after extensive vaccination against H. influenzae type b.

Authors:  José Campos; Margarita Hernando; Federico Román; María Pérez-Vázquez; Belén Aracil; Jesús Oteo; Edurne Lázaro; Francisco de Abajo
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

5.  Antibiotic resistance in Haemophilus influenzae decreased, except for beta-lactamase-negative amoxicillin-resistant isolates, in parallel with community antibiotic consumption in Spain from 1997 to 2007.

Authors:  Silvia García-Cobos; José Campos; Emilia Cercenado; Federico Román; Edurne Lázaro; María Pérez-Vázquez; Francisco de Abajo; Jesús Oteo
Journal:  Antimicrob Agents Chemother       Date:  2008-05-27       Impact factor: 5.191

6.  Capsule gene analysis of invasive Haemophilus influenzae: accuracy of serotyping and prevalence of IS1016 among nontypeable isolates.

Authors:  Sarah W Satola; Julie T Collins; Ruth Napier; Monica M Farley
Journal:  J Clin Microbiol       Date:  2007-08-15       Impact factor: 5.948

7.  Epidemiology of vaccine-preventable invasive diseases in Catalonia in the era of conjugate vaccines.

Authors:  Pilar Ciruela; Ana Martínez; Conchita Izquierdo; Sergi Hernández; Sonia Broner; Carmen Muñoz-Almagro; Àngela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-09       Impact factor: 3.452

8.  Invasive Haemophilus influenzae Disease, Europe, 1996-2006.

Authors:  Shamez Ladhani; Mary P E Slack; Paul T Heath; Anne von Gottberg; Manosree Chandra; Mary E Ramsay
Journal:  Emerg Infect Dis       Date:  2010-03       Impact factor: 6.883

9.  Invasive Haemophilus influenzae serotype e and f disease, England and Wales.

Authors:  Shamez N Ladhani; Sarah Collins; Anna Vickers; David J Litt; Carina Crawford; Mary E Ramsay; Mary P E Slack
Journal:  Emerg Infect Dis       Date:  2012-05       Impact factor: 6.883

10.  Nasopharyngeal and Adenoid Colonization by Haemophilus influenzae and Haemophilus parainfluenzae in Children Undergoing Adenoidectomy and the Ability of Bacterial Isolates to Biofilm Production.

Authors:  Urszula Kosikowska; Izabela Korona-Głowniak; Artur Niedzielski; Anna Malm
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.